With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
In mouse models, IDH1 mutations—recognized to confer hyper-dependence on de novo pyrimidine synthesis—predicted a clinical response and even survival benefit with a novel therapeutic inhibitor of pyrimidine synthesis for gliomas across grade. | Shi, ASTRO 2021
Comments
Post a Comment